REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Aug 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-13

Reporting Person: YANCOPOULOS GEORGE (Director, President and Chief Scientific)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-13	Common Stock	S	773	$625.0	Disposed	936710	Direct
2021-08-16	Common Stock	S	46925	$625.25	Disposed	889785	Direct
2021-08-16	Common Stock	S	2302	$626.1	Disposed	887483	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5848	Indirect
Common Stock	213693	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 46,925 shares of Company stock on August 16, 2021 at prices ranging from $625.00 to $625.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3: Represents volume-weighted average price of sales of 2,302 shares of Company stock on August 16, 2021 at prices ranging from $626.00 to $626.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F4: As investment trustee of trusts for the benefit of the reporting person's children.